Are there alternative ways to support employees who seek weight loss medications
Pharma Industry 3 min read WHO backs GLP-1 treatments to tackle obesity epidemic On Monday, the United Nations health agency issued its first guidelines on how such drugs could be used as a key tool for treating obesity in adults as a chronic, relapsing disease
11 Therefore, any undesirable GLP-1R activity could promote the pathology associated with Parkinsons disease, or future therapeutic options may be able to regulate GLP-1R actions to delay or prevent the manifestation of this disease
Eli Lilly subsequently attempted to patent this as their discovery but it was rejected in court due to the prior publication by Bloom's group (Bloom email)
Research from National Library of Medicine in 2024 also suggests GLP-1 drugs are linked to adverse gastrointestinal events, including nausea, vomiting, delayed gastric emptying and pancreatitis
For the medical device industry, the consequences of the GLP-1 revolution could be devastating indeed
